Clinical Trials

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07431281 2026-04-13

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

2,130 enrolled

Phase 2 Active not recruiting

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03505320 2026-04-03

ILUSTRO

143 enrolled

Phase 3 Active not recruiting

Neoplasms, Stomach Neoplasms

NCT05568095 2026-04-02

STAR-221

1,040 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07221149 2026-04-02

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Phase 2/3 Recruiting

690 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05267626 2026-03-31

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Recruiting

159 enrolled

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT03044613 2026-03-23

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

32 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT05187182 2026-03-18

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Phase 1 Recruiting

42 enrolled

Phase 2 Active not recruiting

Esophageal Neoplasms, Stomach Neoplasms

NCT06256328 2026-03-13

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

226 enrolled

Stomach Neoplasms

NCT04900818 2026-03-05

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

330 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT07432295 2026-02-25

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Phase 2 Recruiting

180 enrolled

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT05867121 2026-02-02

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

GastrointestinalGenitourinaryThoracic

102 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05802056 2025-12-19

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Phase 1 Recruiting

15 enrolled

Phase 1/2 Active not recruiting

Stomach Neoplasms

NCT04396821 2025-12-17

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

150 enrolled

Phase 3 Active not recruiting

Pancreatic Neoplasms, Stomach Neoplasms

NCT05111626 2025-12-15

FORTITUDE-102

515 enrolled

Stomach Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05322577 2025-12-05

FORTITUDE-103

Phase 1/2 Active not recruiting

72 enrolled

Stomach Neoplasms

NCT06452329 2025-12-04

A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Completed

260 enrolled

Phase 1/2 Active not recruiting

Stomach Neoplasms

NCT04180371 2025-11-17

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

288 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04208958 2025-10-27

ConsortiumIO

DermatologicGastrointestinal

56 enrolled 11 charts

Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT06253611 2025-09-22

BIG

Phase 2 Recruiting

120 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Stomach Neoplasms

NCT04278144 2025-09-15

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Phase 1/2 Terminated

175 enrolled

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

145 enrolled 47 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02872116 2025-08-07

CheckMate649

2,031 enrolled 19 charts 2 FDA

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologic

138 enrolled

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07098104 2025-08-01

A Benefit Population Atlas of nICT Versus nCT for LAGC

Completed

291 enrolled

Stomach Neoplasms

NCT03662659 2025-02-05

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Phase 2 Completed

274 enrolled 19 charts

Stomach Neoplasms

NCT03453164 2024-09-19

Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)

41 enrolled 8 charts

Phase 3 Active not recruiting

Stomach Neoplasms

NCT05144854 2024-09-05

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

626 enrolled

Stomach Neoplasms

NCT03172416 2024-05-29

PIPAC

GastrointestinalGynecologic

21 enrolled

Peritoneal Neoplasms, Stomach Neoplasms

NCT02267343 2024-05-03

Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer

493 enrolled

Stomach Neoplasms

NCT02746796 2024-05-03

Study of ONO-4538 in Gastric Cancer

Phase 2/3 Completed

680 enrolled

Stomach Neoplasms

NCT03006705 2024-05-03

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

800 enrolled

Stomach Neoplasms

NCT04062656 2024-03-12

IMAGINE

Phase 2 Unknown

21 enrolled

Stomach Neoplasms

NCT06196554 2024-01-09

Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs

Unknown

40 enrolled

Stomach Neoplasms

NCT05859477 2024-01-02

NIVOFGFR2

Phase 2 Unknown

23 enrolled

Stomach Neoplasms

NCT06008925 2023-08-24

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Phase 1/2 Recruiting

43 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Stomach Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02983045 2023-03-13

PIVOT-02

BreastDermatologicGastrointestinalGenitourinaryThoracic

557 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03995017 2023-02-01

RiME

Phase 1/2 Unknown

34 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Stomach Neoplasms

NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

52 enrolled 25 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05535569 2022-09-10

Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer

50 enrolled

Stomach Neoplasms

NCT03409848 2022-05-18

INTEGA

Phase 2 Completed

97 enrolled